Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice

Katsunori Nonogaki, Takao Kaji

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pharmacologic stimulation of serotonin 5-HT4 receptors increased plasma active glucagon-like-peptide-1 (GLP-1) levels independent of feeding, and that pharmacologic stimulation of 5-HT4 receptors and pharmacologic inhibition of dipeptidyl peptidase-4 exerted synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.

Original languageEnglish
Pages (from-to)e18-e21
JournalDiabetes Research and Clinical Practice
Volume110
Issue number3
DOIs
Publication statusPublished - 2015 Dec 1

Keywords

  • 5-HT4 receptor agonist
  • Alogliptin
  • DPP-4 inhibitor
  • GLP-1
  • Glucose tolerance
  • Mosapride

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice'. Together they form a unique fingerprint.

  • Cite this